Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financi... ( -- Currently enrolling patients in U....)

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

Date:3/26/2008

-- Currently enrolling patients in U.S. Phase II clinical trial for cocaine

addiction -- Expect to initiate U.S. Phase II clinical trial for methamphetamine

addiction in second quarter of 2008

CORAL GABLES, Fla., March 26 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended December 31, 2007.

Commenting on the year, Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners, noted, "Operationally, 2007 was an important year for Catalyst, during which time we achieved several key milestones. Most notably, we developed CPP-109, Catalyst's finished dosage form of vigabatrin, which is now being used in our first U.S. Phase II clinical trial. We also reported successful results of the use of vigabatrin to treat cocaine addiction, from a New York University, investigator-sponsored, double-blind, placebo-controlled Phase II trial in Mexico that was partially supported by Catalyst. That trial confirmed the positive results of the prior two Mexican human pilot studies."

Mr. McEnany continued, "In preparation for our clinical development efforts, we have also strengthened our management team with two key appointments. Steven R. Miller, Ph.D. joined the Company as Vice President of Pharmaceutical Development and Project Management and Patrick Kenny came on board as Director - Corporate Clinical Compliance."

"During 2007, we expanded our Scientific Advisory Board with two new members; Dr. Thomas Kosten, the Waggo
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

Post Your Comments:

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financi...( -- Currently enrolling patients in U....),Health